NRP-1 binding inhibitory peptides and uses thereof
A number of anti-angiogenic strategies connected with the VEGF signalling pathway are used in current clinical treatment or trial phase, but they either cause adverse effects or are not specific. Various strategies were aimed at identifying peptides inhibiting the VEGF-A 165 /NRP-1 interaction. A well-known antiangiogenic peptide is the heptapeptide termed “A7R” having the amino acid sequence ATWLPPR, for which various derivatives have been synthesized, which include peptides having the general sequence Lys(hArg)-AA 2 -AA 3 -Arg. However, the ability of the known peptides to inhibit the VEGF-A 165 /NRP-1 interaction was too low for their use as candidate drugs for inhibiting angiogenesis in subjects in need thereof. The present inventors have now conceived a family of novel peptide-like compounds having a nanomolar affinity for NRP-1, which are thus endowed with a powerful capacity to inhibit the VEGF-A 165 /NRP-1 interaction. These novel peptide-like compounds may be relevantly used as antiangiogenic compounds, especially in subjects affected with cancer.
1 . A compound of formula (I) below:
wherein,
for groups R1 and R4,
a) R1 is a group of formula
and R4 is H, or
b) R1 and R4, together with the carbon and nitrogen atoms to which they are linked, form a pyrrolidinyl ring, or
c) R1 and R4, together with the carbon and nitrogen atoms to which they are linked, form a 2,5-dihydro-1-H-pyrrolyl ring, or
d) R1 and R4, together with the carbon and nitrogen atoms to which they are linked, form a octahydro-1H-indolyl ring, or
e) R1 is a group of formula
and R4 is H,
for groups R2 and R5,
a) R2 is a group of formula
and R5 is H, or
b) R2 is a group of formula
and R5 is H, or
c) R2 and R5, together with the carbon and nitrogen atoms to which they are linked, form a pyrrolidinyl ring, or
d) R2 and R5, together with the carbon and nitrogen atoms to which they are linked, form a 2,5-dihydro-1-H-pyrrolyl ring, or
e) R2 and R5, together with the carbon and nitrogen atoms to which they are linked, form a octahydro-1H-indolyl ring, or
f) R2 is a group of formula
and R5 is H, or
g) R2 is a group of formula
and R5 is H,
A is selected in the group of formulas A1 and A2 below:
wherein A1 is of the formula:
wherein X1 is selected in the group consisting of H, —C(═O)—CH3 and an amine protecting group, and
wherein R3 is selected in the group consisting of
a) R3 is a group of formula
or
b) R3 is a group of formula
or
c) R3 is a group of formula
or
d) R3 is a group of formula
and wherein X2 is selected in the group consisting of H, —C(═O)—CH3 and an amine protecting group,
and
wherein A2 is of the formula below:
wherein X3 and X4, which are identical or different, and are selected from the group consisting of H, —C(═O)—CH3 and an amine protecting group,
provided that the compound of formula (I) does not consist of the peptide CKPPR or CTKPR,
and pharmaceutically acceptable salts and/or racemic, enantiomeric, diastereoisomeric or tautomeric forms thereof.
2 . The compound of formula (I) according to claim 1 , wherein A is A1, and R3 is a group of formula
and R1, R2, R4, R5, X1 and X2 are as defined in claim 1 .
3 . The compound of formula (I) according to claim 1 , wherein A is A1 and R1 and R4, together with the carbon and nitrogen atoms to which they are linked, form a 2,5-dihydro-1-H-pyrrolyl ring, and R2, R3, R5, X1 and X2 are as defined in claim 1 .
4 . The compound of formula (I) according to claim 1 , wherein group A is A1, wherein R1 and R4, together with the carbon and nitrogen atoms to which they are linked, form a octahydro-1H-indolyl ring, and R2, R3, R5, X1 and X2 are as defined in claim 1 .
5 . The compound of formula (I) according to claim 1 , wherein group A is A1, wherein R2 is a group of formula
and R5 is H, and R1, R3, R4, X1 and X2 are as defined in claim 1 .
6 . The compound of formula (I) according to claim 1 , wherein group A is A1, wherein R1 and R4, together with the carbon and nitrogen atoms to which they linked, form a octahydro-1H-indolyl [Oic] ring, R2 is a group of formula
and R5 is H, R3 is a group of formula
and wherein X1 and X2 are as defined in claim 1 .
7 . The compound of formula (I) according to claim 1 , wherein group A is A2 wherein R1 and R4, together with the carbon and nitrogen atoms to which they linked, form a 2,5-dihydro-1-H-pyrrolyl [ΔPro], and R2, R5 and X3 and X4 are as defined in claim 1 .
8 . The compound of formula (I) according to claim 1 , wherein group A is A2, wherein R2 is a group of formula
and R5 is H, [Dab], and R1, R4 and X3, and X4, are as defined in claim 1 .
9 . The compound of formula (I) according to claim 1 , wherein group A is A2, wherein R1 and R4, together with the carbon and nitrogen atoms to which they linked, form a 2,5-dihydro-1-H-pyrrolyl [ΔPro], R2 is a group of formula
and R5 is H, [Dab], and X3, and X4 are as defined I claim 1 .
10 . The compound of formula (I) according to claim 1 , having the formula (I-A) below:
11 . The compound of formula (I) according to claim 1 , having the formula (I-B) below:
12 . The compound of formula (I) according to claim 1 , having the formula (I-C) below:
13 . The compound of formula (I) according to claim 1 , having the formula (I-D) below:
14 . A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 .
15 . A method for treating breast cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt and/or racemic, enantiomeric, diastereoisomeric or tautomeric form thereof.